CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 27,116	$ 27,281	$ 27,305
Costs and expenses:
Cost of goods sold	6,498	5,657	6,601
Research and development expenses	5,718	4,977	4,601
Acquired in-process research and development expenses	1,155	944	939
In-process research and development impairments	50	2,700	0
Selling, general and administrative expenses	6,090	5,673	5,246
Total costs and expenses	19,511	19,951	17,387
Operating income	7,605	7,330	9,918
Interest expense	(944)	(935)	(1,001)
Other income (expense), net	198	(581)	(639)
Income before income taxes	6,859	5,814	8,278
Income tax expense	(1,247)	(1,248)	(2,077)
Net income	5,613	4,566	6,201
Net loss attributable to noncontrolling interest	52	26	24
Net income attributable to Gilead	$ 5,665	$ 4,592	$ 6,225
Basic earnings per share attributable to Gilead (in dollars per share)	$ 4.54	$ 3.66	$ 4.96
Shares used in basic earnings per share attributable to Gilead calculation (in shares)	1,248	1,255	1,256
Diluted earnings per share attributable to Gilead (in dollars per share)	$ 4.50	$ 3.64	$ 4.93
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)	1,258	1,262	1,262
Product sales
Revenues:
Total revenues	$ 26,934	$ 26,982	$ 27,008
Royalty, contract and other revenues
Revenues:
Total revenues	$ 182	$ 299	$ 297